The European Organization for Research and Treatment of Cancer quality of life questionnaire: Translation and reliability study of the Thai version

Journal of the Medical Association of Thailand

Volumn 85, Issue 11, 2002, Pages 1210-1219

  Sirisinha, Thitiya ^a   Jirajarus, Manmana ^a   Silpakit, Chatchawan ^b   Tanvetyanon, Tawee ^c   Ratanatharathorn, Vorachai ^a   Sirilerttrakul, Suwanee ^a   Sirachainan, Ekapop ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

EORTC QLQ C30 Thai version; Quality of life

Indexed keywords

ARTICLE; CANCER; CONTROLLED STUDY; FEMALE; HUMAN; LANGUAGE; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; QUESTIONNAIRE; RELIABILITY; SELF REPORT; THAILAND; VALIDATION PROCESS;

EUROPE; FEMALE; HUMANS; MALE; NEOPLASMS; PROGRAM EVALUATION; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; RESEARCH; SENSITIVITY AND SPECIFICITY; SICKNESS IMPACT PROFILE; THAILAND; TRANSLATIONS;

EID: 0036881386     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Osaba D, The quality of life committee of the clinical trials group of the National Cancer Institute of Canada: Organization and functions. Qual Life Res 1992; 1: 203-11.
2. Ganz PA, Bernhard J, Hurny C. Quality of life and psychosocial oncology research in Europe: State of the art. J Psychol Soc Oncol 1991; 9: 1-22.
3. American Cancer Society. American Cancer Society's second workshop on methodology in behavioral and psychosocial cancer research. Cancer 1991; 67: 765-867.
4. Aaronson NK, Cull AM, Kaasa S, Sprangers AG. The European Organization for Research and Treatment of Cancer (EORTC) modular approach to quality of life assessment in oncology: An update. in Spilker B (ed): Quality of Life and Pharmacoeconomics in Clinical Trials, Second Edition. Philadelphia: Lippincott-Raven Publishers, 1996: 179-88.
5. Osaba D, Aaronson NK, Zee B, et al. Modification of the EORTC. QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. Qual Life Res 1997; 6: 103-8.
6. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy Scale: Development and validation of the general measure. J Clin Oncol 1993; 11: 570-9.
7. Bonomi AE, Cella DF, Hahn EA, et al. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual Life Res 1996; 5: 309-20.
8. Ratanatharathorn V, Sirilerttrakul S, Jirajarus M, et al. Quality of life, Functional Assessment of Cancer Therapy-General. J Med Assoc Thai 2001; 84: 1430-42.
9. Fayers P, Bottomley A, on the behalf of the EORTC quality of life group and the quality of life unit. Quality of life research within the EORTC - the EORTC QLQ-C30. Eur J Can 2002; 38: S125-33.
10. Aaronson NK, Ahmedzai SA, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
11. Schipper H, Clinch J, Powell V. Definition and conceptual issues, In Spilker B, ed. Quality of life assessment in clinical trials. New York: Raven Press, 1990: 11-24.
12. Aaronson NK, Bullinger M, Ahmedzai S. A modular approach to quality of life assessment in cancer clinical trial. Recent Results Cancer Res 1988; 111: 231-49.
13. Cull A, Sprangers M, Bjordal K, Aaronson N. EORTC quality of life study group translation procedure. EORTC, Brussels 1998: 1-26.
14. Cull AM. Cancer-specific quality of life questionnaires: The state of the art in Europe. Eur J Cancer 1997; 33 (Suppl 6): S3-7.
15. rd edition) European Organization for Research and Treatment of Cancer, Brussel 2001.
16. Fayers P, Curran D, Macin D, on the behalf of the EORTC quality of life study group. Incomplete quality of life data in randomized trials: Missing items. Stat Med 1998; 17: 679-96.
17. Kobayashi K, Takeda F, Teramukai S, et al. A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer. Eur J Cancer 1998; 6: 810-5.
18. Montazeri A, Harirchi I, Vahdani M, et al. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Translation and validation study of the Iranian version. Support Care Cancer 1999; 7: 4006.
19. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16: 297-302.
20. Nunnally JC. Psychometric theory. New York: McGraw-Hill, 1994: 1-736.
21. Cella D. Quality of life. In Halland JC (ed) PsychoOncology. New York: Oxford University Press, 1998: 1135-46.
22. De Boer JB, Sprangers MAG, Aaronson NK, et al. The Feasibility, validity and reliability of the EORTC QLQ-C30 in assessing the quality of life of patients with symptomatic HIV infection or AIDA. Psychol Health 1994; 9: 65-77.
23. Ringdal GI, Ringdal K. Testing the EORTC quality of life questionnaire on cancer patients with heterogeneous diagnosis. Qual Life Res 1993; 2: 129-40.
24. Larsson G, von Essen L, Sjoden PO. Health-related quality of life in patients with endocrine tumors of the gastrointestinal tract. Acta Oncologica 1994; 38: 481-90.
25. Caalsson M, Homrin E. Measurement of quality of life satisfaction questionnaire (LSQ-32) and comparison with the EORTC QLQ-C30. Quality Life Res 1996; 5: 265-74.
26. Bjordal K, Freng A, Thorvik J, et al. Patient's selfreported and clinical-rated quality of life in head and neck cancer patients: A cross-sectional study. Oral Oncol Eur J Cancer 1995; 4: 235-41.
27. Maher EJ, Mackenzie C, Young T, et al. The use of the Hospital Anxiety and Depression scale (HADS) and the EORTC QLQ-C30 questionnaires to screen for treatable unmet needs in patients attending routinely for radiotherapy. Cancer Treat Rev 1996; 22: 123-9.
28. Smets EM, Garssen B, Schuster UA, et al. Fatigue in cancer patients. Br J Cancer 1993; 68: 220-4.
29. Stone P, Richards M, A'Hern R, et al. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol 2000; 11: 561-7.
30. Forair P, Hoppe RT, Bloom J, et al. Psychosocial problems among survivors of hodekin's disease. J Clin Oncol 1986; 4: 805-14.
31. Ulander K, Jeppsson B, Grahn G. Quality of life and independence in activities of daily living preoperatively and at follow-up in patients with colorectal cancer. Support Care Cancer 1997; 5: 402-9.
32. Longman AL, Braden CJ, Mishel MH. Side effects burden in women with breast cancer. Cancer Pract 1996; 4: 274-80.
33. Robinson KD, Posner JD, Mishel MH. Patterns of self-care needs and intervention related to biologic response modifier therapy: Fatigue as a model. Semin Oncol Nurs 1992; 8 (Suppl): 17-22.
34. Osaba D, Slamon DJ, Burchmore M, et al. Effects on quality of life of combines trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 2002; 20: 3106-13.